7Baggers
 Published on: 2025-11-15 13:07:28  newser.com Sat, 15 Nov 2025 19:07:28 GMT
 published on: 2025-11-15 06:06:23  newser.com Sat, 15 Nov 2025 12:06:23 GMT
 Akari Therapeutics reports promising data for novel ADC payload By Investing.com  Investing.com Nigeria Tue, 11 Nov 2025 06:58:14 GMT
 Akari Therapeutics (AKTX) Reveals New Data on ADC Payload PH1  GuruFocus Mon, 10 Nov 2025 15:09:04 GMT
 Akari Therapeutics reports promising data for novel ADC payload  Investing.com Mon, 10 Nov 2025 14:13:35 GMT
 published on: 2025-11-09 12:52:34  newser.com Sun, 09 Nov 2025 18:52:34 GMT
 published on: 2025-11-09 00:52:14  newser.com Sun, 09 Nov 2025 06:52:14 GMT
 Akari Therapeutics’ Accepted Abstract Showcasing its Novel  GlobeNewswire Tue, 04 Nov 2025 14:25:00 GMT
 published on: 2025-11-04 02:28:12  newser.com Tue, 04 Nov 2025 08:28:12 GMT
 published on: 2025-11-02 02:50:49  newser.com Sun, 02 Nov 2025 07:50:49 GMT
 published on: 2025-11-01 05:04:12  newser.com Sat, 01 Nov 2025 10:04:12 GMT
 published on: 2025-11-01 03:43:51  newser.com Sat, 01 Nov 2025 08:43:51 GMT
 akari therapeutics announces formation of sab  MSN Sat, 01 Nov 2025 07:24:38 GMT
 aktx sec filings - akari therapeutics plc 10-k, 10-q, 8-k forms  Stock Titan Thu, 30 Oct 2025 12:16:50 GMT
 published on: 2025-10-30 04:33:19  newser.com Thu, 30 Oct 2025 09:33:19 GMT
 published on: 2025-10-30 02:00:59  newser.com Thu, 30 Oct 2025 07:00:59 GMT
 Akari Therapeutics Announces Formation of Scientific  GlobeNewswire Thu, 30 Oct 2025 07:00:00 GMT
 Akari Therapeutics (AKTX) Establishes New Scientific Advisory Bo  GuruFocus Thu, 30 Oct 2025 07:00:00 GMT
 akari therapeutics plc r (cla.mu) stock price, news, quote and history  Yahoo! Finance UK Wed, 29 Oct 2025 12:03:46 GMT

Akari Therapeutics, Plc
(NASDAQ:AKTX) 

AKTX stock logo

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase I...

Full Time Employees: 10
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends